CollPlant to switch Nasdaq ticker to OPHI on Nov. 13
The ticker transition requires no shareholder action; the proposed corporate name change is separately subject to approval and consent.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CollPlant Biotechnologies Ltd. said its ordinary shares will begin trading on Nasdaq under the new ticker OPHI at the open on November 13, 2026; they trade as CLGN through the close on November 12. The shares remain listed on Nasdaq, and shareholders need take no action for the ticker change.
The company intends to change its name to OptiPhi Computing Ltd., subject to shareholder approval at its extraordinary general meeting scheduled for November 24, 2026, and consent from the Israeli Registrar of Companies. CollPlant said the ticker change reflects its strategic expansion into photonic computing through subsidiary LightSolver, while it retains its proprietary plant-derived recombinant human collagen and bio-ink assets for 3D bioprinting and medical aesthetics.
Key Terms
photonic computing technical
Laser Processing Unit (LPU)™ technical
recombinant human collagen (rhCollagen) technical
bio-ink technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will CLGN start trading under OPHI?
Is CLGN changing its name to OptiPhi Computing Ltd.?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On November 12, 2026, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI”.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Attached hereto and incorporated by reference herein are the following exhibits:
| 99.1 | Press Release, dated November 12, 2026. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| COLLPLANT BIOTECHNOLOGIES LTD. | |||
| Date: November 12, 2026 | By: | /s/ Eran Rotem | |
| Name: | Eran Rotem | ||
| Title: | Chief Executive Officer and Chief Financial Officer | ||
2
Exhibit 99.1
CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI”
OPHI marks another important step in CollPlant’s
strategy to expand and focus its operations built
around LightSolver’s all-optical Laser Processing Unit (LPU)™
REHOVOT, Israel, November 12, 2026 -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) (“CollPlant”) today announced that its ordinary shares will begin trading on Nasdaq under the new ticker symbol “OPHI,” effective at the open of trading on November 13, 2026. The shares will continue to trade under “CLGN” through the close of trading on November 12, 2026.
No action is required by shareholders in connection with the ticker symbol change. The ordinary shares will continue to be listed on Nasdaq and CollPlant’s CUSIP number will remain unchanged.
“Changing our ticker symbol to OPHI reflects our strategic expansion into photonic computing,” said Eran Rotem, Chief Executive Officer and CFO of CollPlant. “By building our future around LightSolver’s LPU technology, we believe we are positioned to address next-generation computing demands and deliver long-term value to our shareholders.”
“As the world’s demand for computing power keeps growing, the industry is looking for fundamentally new approaches,” said Dr. Ruti Ben Shlomi, Co-Founder and CEO of LightSolver. “Our LPU uses interacting lasers to perform the computation itself, with the potential to solve demanding workloads at significantly higher speeds while reducing energy consumption.”
Subject to shareholder approval at CollPlant’s extraordinary general meeting scheduled for November 24, 2026 and the consent of the Israeli Registrar of Companies, CollPlant intends to change its name to OptiPhi Computing Ltd. For additional details, please see CollPlant’s announcement dated November 4, 2026.
About CollPlant
CollPlant (Nasdaq: CLGN) is an innovative technology company operating at the intersection of deep-tech photonic computing and advanced biotechnology. Through its subsidiary LightSolver, CollPlant is advancing the development of proprietary all-optical laser-based computing architectures designed to resolve the world’s most demanding computational bottlenecks across artificial intelligence, aerospace, financial engineering, and high-performance computing. CollPlant also retains its proprietary plant-derived recombinant human collagen (rhCollagen) and bio-ink assets, for 3D bioprinting of tissues and organs and medical aesthetics. For more information about CollPlant, visit www.collplant.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the expected timing of trading of CollPlant’s ordinary shares under the new ticker symbol; the proposed change of CollPlant’s name; the anticipated performance, capabilities and energy efficiency of the LPU; the long-term value of CollPlant’s photonic computing business; and the future prospects, business plans and growth strategies of CollPlant and LightSolver. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “continue,” “potential” and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the risk that shareholder approval of the proposed name change or the consent of the Israeli Registrar of Companies is not obtained, or that the name approved differs from the proposed name; LightSolver’s ability to scale its technology from prototype to a commercial product; risks associated with integrating LightSolver’s business, operations and personnel; LightSolver’s ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver’s technology; the ability to develop and commercialize LightSolver’s products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant’s ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investors Contact
CollPlant Biotechnologies
investors@lightsolver.com
Arx Investor Relations
North American Equities Desk
collplant@arxhq.com